stay updated

Khondrion is collaborating globally on its way to market

In July 2018 Khondrion was awarded €2.3M funding from the highly competitive EU Horizon 2020 SME instrument program to progress clinical development...

Khondrion features in new video from Catalyze-Group®

Khondrion granted Orphan Drug Designation for KH176 for the treatment of MIDD from European Commission

Khondrion granted Orphan Drug Designation for KH176 for the treatment of maternally inherited diabetes and deafness (MIDD) from European Commission...

Scientific publication in Cell Death & Disease

Results from collaborative preclinical research effort investigating Leigh disease patient cells published in Cell Death and Disease NIJMEGEN, the...

Publication of the KHENERGY study results

KHENERGY study provides first data on safety and efficacy of KH176 in patients with mitochondrial disease. Results from phase IIa study of innovative reduction-oxidation modulator published in Clinical Pharmacology and Therapeutics.

Khondrion awarded H2020 SME Instrument grant

Khondrion receives €2.3M funding from EU Horizon 2020 SME instrument phase 2 program.

Patient Perspective: A conversation with Kasey Woleben – Co-founder, and Sophia Zilber – Board Member, Patient Registry Director, Cure Mito Foundation

We recently sat down with Kasey Woleben, Co-founder, and Sophia Zilber, Board Member and Patient Registry Director of Cure Mito Foundation, to talk...

2021 – A Year in Review

As 2021 draws to a close, Khondrion’s CEO Jan Smeitink reflects on the past year and the continued progress Khondrion has made in its development of...

Movement disorders in children with primary mitochondrial disease

Movement, the act or process of moving, the change of place or position or posture, is a complex process under the control of many different parts...

A coffee with the Scientific Advisory Board: Prof. Dr. Anu Suomalainen Wartiovaara

How did you first hear about Khondrion and the work the company is doing in mitochondrial disease? Jan Smeitink and I have been colleagues since the...

A coffee with the Scientific Advisory Board: Prof. Dr. Shamima Rahman

How did you first hear about Khondrion and the work the company is doing in mitochondrial disease? I first heard about Khondrion from CEO Jan...

Patient Perspective: A conversation with Elja van der Veer – Former IMP Chair

Can you explain a little about the work that International Mito Patients does? International Mito Patients (IMP) is a global network of 16 national...